Agenus Inc. (AGEN)

Market Cap	143.52M
Revenue (ttm)	106.83M
Net Income (ttm)	-35.38M
Shares Out	34.01M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	374,401
Open	4.270
Previous Close	4.290
Day's Range	4.110 - 4.300
52-Week Range	1.380 - 7.340
Beta	1.53
Analysts	Buy
Price Target	14.50 (+243.6%)
Earnings Date	Nov 10, 2025

About AGEN

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2000
• Employees: 316
• Stock Exchange: NASDAQ
• Ticker Symbol: AGEN
• Website: https://www.agenusbio.com

Financial Performance

In 2024, Agenus's revenue was $103.46 million, a decrease of -33.81% compared to the previous year's $156.31 million. Losses were -$227.43 million, -7.54% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for AGEN stock is "Buy." The 12-month stock price target is $14.5, which is an increase of 243.60% from the latest price.

Price Target

$14.5

(243.60% upside)

Analyst Consensus: Buy